Orthopaedic and dental surgical procedures are performed on a large scale and on a daily basis. In most cases, the surgery is successful and, after revalidating, the patient’s quality of life is significantly improved. In some cases however, patients develop an infection after surgery with detrimental effects on clinical outcome and the socio-economic situation. This number of cases is expected to increase due to factors such as an increasingly aging population. At the basis of these infections is the formation of a so called biofilm, a thin layer of microorganisms within an extracellular polymeric substance (EPS). This matrix can shield the microorganisms from the immune system by inducing the formation of a mucosal barrier.

In response to this unmet need, EMCM has, together with its customer, developed a novel strategy to impregnate tissue grafts with infection-controlling agents such as antibiotics with a prolonged release profile. Early clinical trials with these grafts have already shown excellent graft acceptance and reduced microbial activity and EMCM continues optimise this technology to develop innovative tissue products.